Related Experiment Videos
Neurohormonal activation, oxygen free radicals, and apoptosis in the pathogenesis of congestive heart failure
1Division of Pharmacological Sciences, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406-0939, USA.
Insights
Carvedilol, a neurohormonal antagonist and antioxidant, significantly reduces mortality and hospitalizations in congestive heart failure (CHF) patients. It protects the heart by blocking harmful pathways and preventing cell death, slowing disease progression.
Area of Science:
- Cardiology
- Pharmacology
- Biochemistry
Background:
- Congestive heart failure (CHF) involves activated neurohormonal systems (renin-angiotensin, sympathetic, endothelin) and increased reactive oxygen species.
- These processes contribute to cardiac remodeling, apoptosis (programmed cell death), and progressive left ventricular dysfunction in CHF patients.
Purpose of the Study:
- To evaluate the efficacy of carvedilol, a multifaceted neurohormonal antagonist, in managing congestive heart failure (CHF).
- To investigate carvedilol's mechanisms of action, including its beta-blocker, vasodilator, and antioxidant properties, in the context of CHF progression.
Main Methods:
- Double-blind, placebo-controlled clinical trials were conducted to assess carvedilol's impact on mortality and hospitalization rates in CHF patients.
- Hemodynamic effects, including effects on total peripheral vascular resistance and preload, were analyzed.
- The drug's antioxidant and anti-apoptotic activities in myocardial tissue were examined.
Main Results:
- Carvedilol demonstrated a significant 65% reduction in mortality (p <0.001) and decreased hospitalization rates in CHF patients.
- The drug acts as a nonselective beta-blocker and alpha1-adrenoceptor blocker, reducing peripheral vascular resistance and preload without compromising cardiac output or causing reflex tachycardia.
- Carvedilol exhibits potent antioxidant properties, protecting the myocardium from oxygen radical damage and inhibiting apoptosis.
Conclusions:
- Carvedilol is effective in slowing the progression of CHF by antagonizing neurohormonal systems and reducing oxidative stress.
- Its ability to inhibit myocardial apoptosis, attributed to its antioxidant activity, likely contributes to reduced mortality and disease progression in CHF.
- Carvedilol's combined neurohormonal antagonism, vasodilatory effects, and antioxidant properties offer a comprehensive therapeutic approach for managing CHF.
Abstract:
A variety of pathophysiologic processes are activated in patients with congestive heart failure (CHF), and some of these have been implicated in the progression of the disease. The most important processes to be activated in CHF are the neurohormonal systems, which include the renin-angiotensin system, the sympathetic nervous system, and the endothelin system. In addition to the neurohormonal systems, the formation of reactive oxygen free radicals is increased in patients with CHF. It has been postulated that stimulation of neurohormonal pathways and the formation of oxygen free radicals ultimately lead to the activation of a family of transcription factors that are involved in cardiac remodeling, which is a hallmark of CHF. In addition, the formation of oxygen free radicals has been implicated in the process of apoptosis or programmed cell death, which may be responsible for a continued loss of myocardial cells, resulting in the progressive decrease in left ventricular function that occurs over time in patients with CHF. Carvedilol is a multiple-action neurohormonal antagonist that is effective in slowing the progression of CHF. In double-blind, placebo-controlled clinical trials, carvedilol decreased mortality by 65% (p <0.001) and significantly reduced hospitalization. Carvedilol is a nonselective beta-blocker and vasodilator, the latter activity resulting from alpha1-adrenoceptor blockade. The hemodynamic responses produced by carvedilol result primarily from the blockade of beta1-, beta2-, and alpha1-adrenoceptors. Carvedilol reduces total peripheral vascular resistance and preload without significantly compromising cardiac output or eliciting reflex tachycardia. Carvedilol is also a potent antioxidant that may protect the myocardium from damage produced by oxygen radicals and, as a consequence of its antioxidant activity, carvedilol also inhibits apoptosis in the myocardium. The ability of carvedilol to inhibit apoptosis in the heart may be responsible, in part, for the ability of the drug to reduce mortality and to inhibit the progression of CHF.